MapLight Therapeutics: Strong Balance Sheet Ahead of Crucial Phase 2 Readouts in Q3 2026

[ad_1] Executive Summary MapLight Therapeutics, Inc. has reported its financial and operational results for the fourth quarter and full fiscal year ended December 31, 2025. Operating as a clinical-stage biopharmaceutical entity, the company continues to execute its strategy centered around…

